Item 5. Other Information
ITEM 5. OTHER INFORMATION
The 2022 Loan Agreement with SLR Investment Corp. provides us the right to borrow an additional $22.5 million on or prior to July 25, 2023; provided that (i) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement and (ii) that we have received approval by the FDA for our NDA for the Hyperphosphatemia Indication by a particular date. On August 1, 2022, we entered into an amendment to the 2022 Loan Agreement to extend the date for approval of our NDA for the Hyperphosphatemia Indication from December 31, 2022 to March 31, 2023.
76
Table of Contents
ITEM 6. Exhibits
Incorporated by Reference
Exhibit
Number Exhibit Description Form Date Number Filed
Herewith
10.1† Royalty and Sales Milestone Interest Acquisition Agreement dated June 29, 2022, by and between Ardelyx, Inc. and Healthcare Royalty Partners IV, L.P.
X
10.2 First Amendment to the Loan and Security Agreement dated August 1, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.
X
10.3# Second Amended and Restated Non-Employee Director Compensation Program
X
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
32.1 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
101 The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL): (i) Condensed Balance Sheets as of June 30, 2022 and December 31, 2021, (ii) Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2022 and 2021, (iii) Condensed Statements of Cash Flows for the three and six months ended June 30, 2022 and 2021, and (iv) Notes to Unaudited Condensed Financial Statements.
X
104 Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.
† Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.
# Indicates management contract or management or non-employee director compensatory plan.
77
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Ardelyx, Inc.
Date: August 4, 2022 By: /s/ Robert Felsch
Robert Felsch
Senior Vice President and Chief Accounting Officer
(Principal Accounting Officer)
78
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the is authoritative for anything you rely on.